Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
Am J Alzheimers Dis Other Demen. 2012 Aug;27(5):296-300. doi: 10.1177/1533317512452034.
At this time there are no effective methods to alter the disease course in Alzheimer's disease. All FDA approved interventions are for symptomatic relief only. However, it is an exciting time as many agents in development have theorhetical potential to impact the disease course. This review discusses some of the agents that have been in clinical trials, particularly those that affect amyloid processing. Some agents have failed while others still provide hope. Since amyloid is the peptide most closely linked to disease pathogenesis, it is possible that some of the anti-amyloid agents will impact the disease progression in a meaningful way.
目前尚无有效方法改变阿尔茨海默病的病程。所有获得 FDA 批准的干预措施都只能缓解症状。然而，这是一个令人兴奋的时刻，因为许多正在开发中的药物具有理论上影响疾病进程的潜力。本综述讨论了一些已进行临床试验的药物，特别是那些影响淀粉样蛋白处理的药物。一些药物已经失败，而另一些药物仍然有希望。由于淀粉样蛋白是与疾病发病机制最密切相关的肽，因此一些抗淀粉样蛋白药物有可能以有意义的方式影响疾病进展。
